Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria

    Risultato della ricerca: Article

    Abstract

    In this paper the clinical value of PET for early prediction of tumor response to Erlotinib in patients with advanced or metastatic nonsmall cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen is evaluated. The aim was to compare the early metabolic treatment response using European Organization for Research and Treatment of Cancer (EORTC) 1999 recommendations and PET Response Criteria in Solid Tumors (PERCIST), and the standard treatment response using Response Evaluation Criteria in Solid Tumors (RECIST).
    Lingua originaleEnglish
    Numero di pagine0
    RivistaTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    Stato di pubblicazionePublished - 2014

      Fingerprint

    Cita questo